NSE: ROSSARI | BSE: 543213

Mid-range Performer

Download real time

527.10 0.40 (0.08%)

31.19% Fall from 52W High

39,527 NSE+BSE Volume

NSE 05 Jun, 2026 2:14 PM (IST)

2,919.7

Market Cap

Above industry Median

Beta 1Year

High Volatility

Rossari Biotech Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for ROSSARI, BSE:543213 Rossari Biotech Ltd.

Search Inside the pdf :

Rossari Biotech Ltd.

30 Apr 2026

527.10

0.08%

Result Update

Buy: Rossari Biotech Ltd.

Target

Deven Choksey

Rossari Biotech closed FY26 on a strong footing, reporting its highest-ever quarterly revenue and EBITDA in Q4, with consolidated revenue from operations for the full year at INR 2,396.4 crore up 15% YoY, driven primarily by volume.

Rossari Biotech Ltd. has an average target of 587.00 from 2 brokers.

Rossari Biotech Ltd.

29 Apr 2026

527.10

0.08%

Focus on profitable growth, improved utilisation and sale of non-core assets in FY27

Buy: Rossari Biotech Ltd.

Recommendation Target

ICICI Securities Limited

Rossari’s Q4 EBITDA grew 11.2% YoY, while gross/EBITDA margins shrank QoQ due to inferior mix. Rossari has outlined its focus areas for FY27. Grow profitably by improving sales in the high-margin categories of pharma, aroma and personal care; separately, the company plans to exit its low-margin B2C business.

Rossari Biotech Ltd. is trading below its 150 day SMA of 534.5

Rossari Biotech Ltd.

21 Jan 2026

527.10

0.08%

HPPC and new capacities to drive earnings growth

Buy: Rossari Biotech Ltd.

Target

Deven Choksey

The near-term headwinds—muted domestic demand, elevated employee costs, and gestation-led pressure from new capacities—are likely to keep earnings growth and return ratios subdued over the next few quarters.

Rossari Biotech Ltd. has an average target of 587.00 from 2 brokers.

Rossari Biotech Ltd.

24 Oct 2025

527.10

0.08%

HPPC and new capacities to drive earnings growth

Buy: Rossari Biotech Ltd.

Target

Deven Choksey

Rossari Biotech continues to execute well operationally, leveraging R&D intensity and export expansion to offset pricing headwinds.

Rossari Biotech Ltd. has an average target of 587.00 from 2 brokers.

Rossari Biotech Ltd.

25 Jul 2025

527.10

0.08%

HPPC and new capacities to drive earnings growth

Buy: Rossari Biotech Ltd.

Deven Choksey

Rossari Biotech’s Q1FY26 revenue grew by 11.0% YoY (-6.2% QoQ) to INR 5,437 Mn., in-line with our estimates, the growth was entirely driven by volume expansion of 11.0% YoY.

Rossari Biotech Ltd. is trading below its 150 day SMA of 534.5

Rossari Biotech Ltd.

22 Oct 2024

527.10

0.08%

Rossari Biotech | Q2FY25 Result Update

Buy: Rossari Biotech Ltd.

Target

Edelweiss

HPPC business and capex to drive growth

Rossari Biotech Ltd. has an average target of 587.00 from 2 brokers.

Rossari Biotech Ltd.

22 Oct 2024

527.10

0.08%

HPPC steady; outlook bright backed by capex, market gain; Buy

Buy: Rossari Biotech Ltd.

Target

Anand Rathi

We expect it is likely to deliver 18%/22%/25% revenue/EBITDA/PAT CAGRs over FY25-27 due to swelling demand, capacity expansion and mounting exports.

Rossari Biotech Ltd. is trading below its 150 day SMA of 534.5

Rossari Biotech Ltd.

21 Oct 2024

527.10

0.08%

Exports drive revenue growth

Hold: Rossari Biotech Ltd.

Recommendation Target

ICICI Securities Limited

Rossari Biotech’s (Rossari) Q2FY25 HPPC revenue growth (+6.2% YoY) was hurt from softer demand and restricted ethylene oxide (EO) capacity.

Rossari Biotech Ltd. is trading above its 100 day SMA of 498.6

Rossari Biotech Ltd.

13 Jun 2024

527.10

0.08%

Diversified business mix; no major China competition; initiating, with a Buy

Buy: Rossari Biotech Ltd.

Anand Rathi

Rossari Biotech is a leading specialty chemicals manufacturing company, focusing on four core chemistries of enzymes, silicones, acrylics and surfactants. It caters to industries such as home and personal care, and performance chemicals (HPPC), textile specialty chemicals (TSC) and animal health and nutrition (AHN) products